Los Angeles Capital Management LLC Has $358,000 Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Los Angeles Capital Management LLC raised its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 8.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 189,660 shares of the company’s stock after acquiring an additional 14,240 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Mersana Therapeutics were worth $358,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRSN. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Mersana Therapeutics in the 1st quarter valued at $226,000. BNP Paribas Financial Markets boosted its stake in shares of Mersana Therapeutics by 90.0% in the 1st quarter. BNP Paribas Financial Markets now owns 80,735 shares of the company’s stock valued at $362,000 after purchasing an additional 38,239 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Mersana Therapeutics by 976.7% in the 1st quarter. Russell Investments Group Ltd. now owns 9,453 shares of the company’s stock valued at $42,000 after purchasing an additional 8,575 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Mersana Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 6,274,370 shares of the company’s stock valued at $28,109,000 after purchasing an additional 36,782 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Mersana Therapeutics by 166.7% in the 1st quarter. Acadian Asset Management LLC now owns 468,923 shares of the company’s stock valued at $2,099,000 after purchasing an additional 293,115 shares during the last quarter. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on MRSN. Citigroup began coverage on shares of Mersana Therapeutics in a research note on Friday. They set a “buy” rating and a $5.00 target price on the stock. Lifesci Capital raised shares of Mersana Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Finally, Robert W. Baird cut their target price on shares of Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Mersana Therapeutics Stock Down 12.3 %

Mersana Therapeutics stock opened at $2.21 on Monday. Mersana Therapeutics, Inc. has a 1-year low of $1.22 and a 1-year high of $6.28. The firm has a market capitalization of $273.01 million, a price-to-earnings ratio of -3.62 and a beta of 1.50. The firm’s fifty day moving average price is $2.03 and its two-hundred day moving average price is $2.05. The company has a current ratio of 2.35, a quick ratio of 2.72 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The firm had revenue of $12.60 million for the quarter, compared to analyst estimates of $7.53 million. During the same period last year, the firm earned ($0.35) earnings per share. The business’s quarterly revenue was up 63.6% compared to the same quarter last year. On average, equities research analysts predict that Mersana Therapeutics, Inc. will post -0.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Mersana Therapeutics

In other news, CEO Martin H. Jr. Huber sold 50,423 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $1.76, for a total value of $88,744.48. Following the completion of the sale, the chief executive officer now owns 116,327 shares in the company, valued at $204,735.52. This represents a 30.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 70,849 shares of company stock valued at $129,184. Corporate insiders own 11.80% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.